Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
4.420
-0.040 (-0.90%)
At close: Aug 13, 2025, 4:00 PM
4.490
+0.070 (1.58%)
Pre-market: Aug 14, 2025, 8:51 AM EDT
Alumis Employees
As of December 31, 2024, Alumis had 170 total employees, including 168 full-time and 2 part-time employees. The number of employees increased by 61 or 55.96% compared to the previous year.
Employees
170
Change (1Y)
61
Growth (1Y)
55.96%
Revenue / Employee
$117,971
Profits / Employee
-$1,338,341
Market Cap
456.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 170 | 61 | 55.96% |
| Dec 31, 2023 | 109 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALMS News
- 17 hours ago - Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 21 days ago - Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus - GlobeNewsWire
- 4 weeks ago - Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 2 months ago - Alumis to Present at the Jefferies Global Healthcare Investor Conference - GlobeNewsWire
- 2 months ago - Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis - GlobeNewsWire
- 3 months ago - Alumis Completes Merger with ACELYRIN - GlobeNewsWire
- 3 months ago - Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - GlobeNewsWire
- 3 months ago - Alumis Stockholders Approve Merger with ACELYRIN - GlobeNewsWire